Wei Shen1, Luyan Bian2, Ying Ma3, Xiuyan Yin4. 1. People's Hospital of Rizhao Rizhao, Shandong, China. 2. Department of Nephrology, Qingdao Municipal Hospital Qingdao, Shandong, China. 3. Tai'an TSCM Hospital Tai'An, China. 4. Department of Ophthalmology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University Qingdao, Shandong, China.
Abstract
OBJECTIVE: To investigate the mechanism of serum interleukin-6 (IL-6) change in disease progression of interstitial nephritis. METHODS: This is a retrospective study. From November 2017 to November 2019, 87 patients with interstitial nephritis treated in our hospital were enrolled and divided into an acute group (n=42) and a chronic group (n=45) based on pathological results of renal biopsies. Forty healthy individuals after physical examination during the same period were enrolled into the reference group. Serum IL-6 levels were determined using the enzyme-linked immunosorbent assay (ELISA). RESULTS: Among the three groups, patients in the acute group showed the highest IL-6 level (P<0.001). The acute group obtained higher serum advanced oxidation protein products (AOPP) levels and glomerular filtration rate (GFR) than the other two groups (P<0.05). The acute group showed lower levels of CD34+ [number of positive microvessels (MVs)/HP], a smaller type III collagen positive area, and a larger type IV collagen positive area than the chronic group (P<0.05). The acute group obtained higher levels of IL-27 and tumor necrosis factor-α (TNF-α) than the chronic group (P<0.001). The acute group had higher levels of serum creatinine (SCr), erythrocyte sedimentation rate (ESR), estimated glomerular filtration rate (eGFR), and 24-hour urine protein quantity (24 h UPQ) than the other groups (P<0.001). The combined detection of serum IL-6, TNF-α, and micro-albumin (mALB) outperformed the stand-alone approach (P<0.05). Serum IL-32 and kidney injury molecule-1 (KIM-1) levels in the acute and chronic group were positively correlated with SCr and 24 h UPQ (P<0.05). CONCLUSIONS: Serum IL-6 shows a great potential as an important marker of disease progression in interstitial nephritis. AJTR
OBJECTIVE: To investigate the mechanism of serum interleukin-6 (IL-6) change in disease progression of interstitial nephritis. METHODS: This is a retrospective study. From November 2017 to November 2019, 87 patients with interstitial nephritis treated in our hospital were enrolled and divided into an acute group (n=42) and a chronic group (n=45) based on pathological results of renal biopsies. Forty healthy individuals after physical examination during the same period were enrolled into the reference group. Serum IL-6 levels were determined using the enzyme-linked immunosorbent assay (ELISA). RESULTS: Among the three groups, patients in the acute group showed the highest IL-6 level (P<0.001). The acute group obtained higher serum advanced oxidation protein products (AOPP) levels and glomerular filtration rate (GFR) than the other two groups (P<0.05). The acute group showed lower levels of CD34+ [number of positive microvessels (MVs)/HP], a smaller type III collagen positive area, and a larger type IV collagen positive area than the chronic group (P<0.05). The acute group obtained higher levels of IL-27 and tumor necrosis factor-α (TNF-α) than the chronic group (P<0.001). The acute group had higher levels of serum creatinine (SCr), erythrocyte sedimentation rate (ESR), estimated glomerular filtration rate (eGFR), and 24-hour urine protein quantity (24 h UPQ) than the other groups (P<0.001). The combined detection of serum IL-6, TNF-α, and micro-albumin (mALB) outperformed the stand-alone approach (P<0.05). Serum IL-32 and kidney injury molecule-1 (KIM-1) levels in the acute and chronic group were positively correlated with SCr and 24 h UPQ (P<0.05). CONCLUSIONS: Serum IL-6 shows a great potential as an important marker of disease progression in interstitial nephritis. AJTR
Authors: Stephen A Strugnell; Stuart M Sprague; Akhtar Ashfaq; Martin Petkovich; Charles W Bishop Journal: Am J Nephrol Date: 2019-03-15 Impact factor: 3.754
Authors: Benjamin A Vervaet; Cynthia C Nast; Channa Jayasumana; Gerd Schreurs; Frank Roels; Chula Herath; Nika Kojc; Vahid Samaee; Sonali Rodrigo; Swarnalata Gowrishankar; Christiane Mousson; Rajeewa Dassanayake; Carlos M Orantes; Vincent Vuiblet; Claire Rigothier; Patrick C D'Haese; Marc E De Broe Journal: Kidney Int Date: 2019-11-23 Impact factor: 10.612
Authors: Vivien Béziat; Simon J Tavernier; Yin-Huai Chen; Cindy S Ma; Marie Materna; Arian Laurence; Jens Staal; Dominik Aschenbrenner; Lisa Roels; Lisa Worley; Kathleen Claes; Lisa Gartner; Lisa A Kohn; Marieke De Bruyne; Klaus Schmitz-Abe; Louis-Marie Charbonnier; Sevgi Keles; Justine Nammour; Natasha Vladikine; Majistor Raj Luxman Maglorius Renkilaraj; Yoann Seeleuthner; Mélanie Migaud; Jérémie Rosain; Mohamed Jeljeli; Bertrand Boisson; Eva Van Braeckel; Jill A Rosenfeld; Hongzheng Dai; Lindsay C Burrage; David R Murdock; Bart N Lambrecht; Véronique Avettand-Fenoel; Tiphanie P Vogel; Charles R Esther; Sule Haskologlu; Figen Dogu; Peter Ciznar; David Boutboul; Marie Ouachée-Chardin; Jean Amourette; Marie-Noëlle Lebras; Clément Gauvain; Colas Tcherakian; Aydan Ikinciogullari; Rudi Beyaert; Laurent Abel; Joshua D Milner; Bodo Grimbacher; Louis-Jean Couderc; Manish J Butte; Alexandra F Freeman; Émilie Catherinot; Claire Fieschi; Talal A Chatila; Stuart G Tangye; Holm H Uhlig; Filomeen Haerynck; Jean-Laurent Casanova; Anne Puel Journal: J Exp Med Date: 2020-06-01 Impact factor: 14.307